21 May 2026
Eris Lifescience guides FY27 revenue growth at 18% to 20%.
This is well ahead of India's pharma industry average of 9 to 10%, driven by chronic therapy launches and integration gains from the Biocon Biologics asset acquisition.
Every Finvezto stock note on Eris Lifesciences, dated and newest first. Coverage spans pharma.
Stock notes are the free daily layer. The membership carries the full Flexi-Wealth system: an ETF core portfolio with monthly rebalancing signals, fifteen quality-momentum stocks with exact weightages every month, options income and hedging recommendations, and the institutional data toolkit. One flat membership covers everything.
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.